Possible drug-drug interactions among elderly patients receiving antiviral therapy for chronic hepatitis B

Basit Öğe Kaydı
dc.authoridAlkan, Sevil / 0000-0003-1944-2477
dc.contributor.authorÇelik, Mehmet
dc.contributor.authorArslan, Yusuf
dc.contributor.authorÖnder, Taylan
dc.contributor.authorAlkan, Sevil
dc.contributor.authorŞahin, Ahmet
dc.contributor.authorAkgül, Fethiye
dc.date.accessioned2025-01-27T21:01:44Z
dc.date.available2025-01-27T21:01:44Z
dc.date.issued2024
dc.departmentÇanakkale Onsekiz Mart Üniversitesi
dc.description.abstractAim To identify possible drug-drug interactions in patients taking medications for other comorbidities while on antiviral therapy for chronic hepatitis B. Methods The study enrolled patients with chronic hepatitis B aged >= 60 years who were treated with antiviral therapy in five hospitals in Turkey between January 1 and March 1, 2023. The Lexicomp (R) Drug Interactions program was used to identify possible drug-drug interactions. Results The study included 213 patients (119 [55.9%] men). The mean age was 68.5 years. A potential drug- drug interaction was identified in 112 patients (52.6%). The most common type of interaction was type C (follow the treatment) (71.54%). The number of potential drug-drug interactions increased with an increase in the number of drugs used by the patients. A robust and affirmative correlation was observed between the number of medications used and the number of possible drug-drug interactions (r = 0.791, P < 0.001). Adverse interactions (interactions of types C and D, 3.7% of cases) were limited to patients receiving tenofovir disoproxil fumarate. Conclusion Nonsteroidal anti-inflammatory medications should be used cautiously in elderly patients with chronic hepatitis B treated with tenofovir disoproxil fumarate due to the increased risk of renal toxicity.
dc.identifier.doi10.3325/cmj.2024.65.305
dc.identifier.endpage312
dc.identifier.issn0353-9504
dc.identifier.issn1332-8166
dc.identifier.issue4
dc.identifier.pmid39219194
dc.identifier.scopus2-s2.0-85203110735
dc.identifier.scopusqualityQ2
dc.identifier.startpage305
dc.identifier.urihttps://doi.org/10.3325/cmj.2024.65.305
dc.identifier.urihttps://hdl.handle.net/20.500.12428/27168
dc.identifier.volume65
dc.identifier.wosWOS:001308042300004
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherMedicinska Naklada
dc.relation.ispartofCroatian Medical Journal
dc.relation.publicationcategoryinfo:eu-repo/semantics/openAccess
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_WoS_20250125
dc.subjectTenofovir Disoproxil Fumarate
dc.subjectEntecavir
dc.subjectPolypharmacy
dc.subjectSafety
dc.titlePossible drug-drug interactions among elderly patients receiving antiviral therapy for chronic hepatitis B
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
Sevil Alkan_Makale.pdf
Boyut:
533.1 KB
Biçim:
Adobe Portable Document Format
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Dahili Tıp Bilimleri Bölümü Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu